These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 28139613)

  • 1. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
    Balabanov R; Lisak D; Beaumont T; Lisak RP; Dore-Duffy P
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.
    Weber MS; Hohlfeld R; Zamvil SS
    Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Cree BAC; Goldman MD; Corboy JR; Singer BA; Fox EJ; Arnold DL; Ford C; Weinstock-Guttman B; Bar-Or A; Mientus S; Sienkiewicz D; Zhang Y; Karan R; Tenenbaum N;
    JAMA Neurol; 2020 Aug; 78(1):1-13. PubMed ID: 32852530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.
    Bellmann-Strobl J; Paul F; Wuerfel J; Dörr J; Infante-Duarte C; Heidrich E; Körtgen B; Brandt A; Pfüller C; Radbruch H; Rust R; Siffrin V; Aktas O; Heesen C; Faiss J; Hoffmann F; Lorenz M; Zimmermann B; Groppa S; Wernecke KD; Zipp F
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33762428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H; Hipp J; Roßnagel F; Moritz C
    Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].
    Boyko AN; Bakhtiyarova KZ; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Fedulov AS; Zinkina-Orikhan AV; Linkova YN; Ivanov RA; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):100-109. PubMed ID: 31934995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    Marsters C; Nathoo N; Amatto L; Wong R; Mahmood MN; McCombe JA
    J Neuroimmunol; 2023 Jul; 380():578110. PubMed ID: 37267695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.
    Selmaj K; Barkhof F; Belova AN; Wolf C; van den Tweel ER; Oberyé JJ; Mulder R; Egging DF; Koper NP; Cohen JA;
    Mult Scler; 2017 Dec; 23(14):1909-1917. PubMed ID: 28090798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on combination therapies for multiple sclerosis: where are we now?
    Sorensen PS; Magyari M; Sellebjerg F
    Expert Rev Neurother; 2023; 23(12):1173-1187. PubMed ID: 38058171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.
    Melamed-Gal S; Loupe P; Timan B; Weinstein V; Kolitz S; Zhang J; Funt J; Komlosh A; Ashkenazi N; Bar-Ilan O; Konya A; Beriozkin O; Laifenfeld D; Hasson T; Krispin R; Molotsky T; Papir G; Sulimani L; Zeskind B; Liu P; Nock S; Hayden MR; Gilbert A; Grossman I
    eNeurologicalSci; 2018 Sep; 12():19-30. PubMed ID: 30094354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil.
    Pipek LZ; Mahler JV; Nascimento RFV; Becker J; Apóstolos-Pereira SL; Adoni T; Silva GD; Callegaro D;
    Arq Neuropsiquiatr; 2024 Jan; 82(1):1-2. PubMed ID: 38316429
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety].
    Boyko OV; Boyko AN; Yakovlev PA; Zinkina-Orikhan AV; Kotov SV; Linkova YN; Prakhova LN; Totolian NA; Shchur SG; Ivanov RA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):87-95. PubMed ID: 31934993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study).
    Marwood L; Taylor R; Goldsmith K; Romeo R; Holland R; Pickles A; Hutchinson J; Dietch D; Cipriani A; Nair R; Attenburrow MJ; Young AH; Geddes J; McAllister-Williams RH; Cleare AJ
    BMC Psychiatry; 2017 Jun; 17(1):231. PubMed ID: 28651526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].
    Boyko AN; Bosenko LP; Vasilovskiy VV; Volkova LI; Zakharova MN; Kotov SV; Lekomtseva EV; Negrich TI; Parshina EV; Patrusheva OP; Prokopenko SV; Sazonov DV; Timchenko PV; Trinitatskiy YV; Khabirov FA; Khavunka MY; Chichanovskaya LV; Sherman MA; Lin'kova YN; Zinkina-Orikhan AV; Tursunova KB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):107-113. PubMed ID: 28617368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
    Tramacere I; Virgili G; Perduca V; Lucenteforte E; Benedetti MD; Capobussi M; Castellini G; Frau S; Gonzalez-Lorenzo M; Featherstone R; Filippini G
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012186. PubMed ID: 38032059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
    Melnikov M; Sharanova S; Sviridova A; Rogovskii V; Murugina N; Nikolaeva A; Dagil Y; Murugin V; Ospelnikova T; Boyko A; Pashenkov M
    PLoS One; 2020; 15(10):e0240305. PubMed ID: 33126239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
    Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.